NASDAQ · Biotechnology

BTAI (BTAI) Stock

$0.14 -15.85% NASDAQ: BTAI Healthcare

Valuation

MetricValue
Price$0.14
Market Cap$4.23M
P/E Ratio-0.14
P/B Ratio-0.08
P/S Ratio32.46
EPS (TTM)$0.00
52-Week High$5.19
52-Week Low$0.12
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE69.92%
ROA-246.05%
ROCE41.19%
Gross Margin-5000.00%
Operating Margin-5000.00%
Net Margin-110.79%
Debt/Equity-0.90
Current Ratio0.83

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$2.0M$1.0M
Operating Profit$-107.0M$-160.0M$-172.0M$-67.0M$-50.0M
Net Profit$-107.0M$-166.0M$-179.0M$-60.0M$-70.0M
EPS$-64.87$-94.67$-98.35$-23.51$-5.73
Op Margin—-42572.0%-12448.0%-2967.6%-7829.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$239.0M$206.0M$74.0M$38.0M$45.0M
Total Liabilities$18.0M$129.0M$130.0M$131.0M$140.0M
Cash$233.0M$194.0M$65.0M$30.0M$28.0M
Borrowings$1.0M$94.0M$101.0M$103.0M$110.0M

Latest News

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock Zacks · Jun 2, 2026 BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting GlobeNewswire · May 28, 2026 BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 15, 2026 BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026 CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates Zacks · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-82.0M$-135.0M$-155.0M$-72.0M$-58.0M
Investing Cash Flow$-1.0M$0$0$0$0
Financing Cash Flow$1.0M$-3.0M$-1.0M$-1.0M$0
Net Cash Flow$20.0M$-39.0M$-129.0M$-35.0M$-1.0M
Free Cash Flow$-83.0M$-135.0M$-155.0M$-72.0M$-58.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-2.17
FCF Yield-211.36%
Quick Ratio0.21
Interest Coverage-2.59
Return 1Y-51.05%
Return 3Y-99.44%
Return 5Y-99.79%

Ownership

Insiders Held3.65%
Institutions Held18.72%
Institutions Float Held19.43%
Institutional HolderSharesReport Date
Millennium Management Llc1,936,7602026-03-31
Armistice Capital, LLC1,910,0762026-03-31
Oaktree Capital Management LP241,1882026-03-31
Geode Capital Management, LLC230,1682026-03-31
Vanguard Capital Management LLC207,3392026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.69 -1.74% -1.54 $71.90M 0.00%
BCAB $1.74 +0.00% -0.12 $2.88M 0.00%
CELU $1.88 +1.62% -0.50 $54.42M 0.00%
EVAXEvaxion Biotech A/S $3.05 +0.66% -1.99 $19.27M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%

About BTAI

BTAI is led by CEO Vimal D. Mehta, employs 37 people, headquartered in US, publicly traded since 2018.

BTAI stock trades at $0.14 with a market capitalization of $4.23M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of -0.08, price-to-sales of 32.46. Over the past 52 weeks the stock has ranged between $0.12 and $5.19, and currently trades 97.3% below its 52-week high.

On profitability, BTAI generates a return on equity (ROE) of 69.92% — well above the market average, a sign of a high-quality business, return on capital employed of 41.19%, an operating margin of -5000.00%, a net profit margin of -110.79%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides